Merck shares results of Islatravir as PrEP trial
Merck, presented the results of a Phase-II trial of islatravir, a long-acting drug, for the treatment and prevention of HIV, at the 11th International Scientific Conference IAS 2021.
Participants received ISL orally once a month for 6 months. After 6 months the treatment ...